Adjunctive canadian Divalproex Sodium Lowers Cholesterol Elevation with Olanzapine generic
Author: Daniel E. Casey, MD, Department of Psychiatry, Oregon Health Sciences University, Portland, Oregon
Cardiovascular disease is a major cause of morbidity and mortality in patients with schizophrenia. Every 1% increase in total cholesterol levels results in a 2% increase in the risk of coronary artery disease.
Continue reading " Psychotherapy and Psychopharmacology: Adjunctive Divalproex "
Five-Year Effects of Rivastigmine on Cognitive Performance
Author: Mary Sano, MD, Professor of Medicine, Mount Sinai School of Medicine, New York, New York
Alzheimer’s disease (AD) is characterized by a relentless decline in cognitive performance and in the ability to perform normal daily tasks. Untreated or placebo-treated patients with AD show an average annual deterioration of about [...]
Continue reading " Psychotherapy and Psychopharmacology: Five-Year Effects "
Duloxetine generic Versus Placebo in Preventing Relapse of Major Depressive Disorder
Author: Michael J. Detke, MD, PhD, Indiana University School of Medicine, Indianapolis, and Medical Director for Cymbalta, Lilly Research Laboratories
It has been well established for more than a decade that major depressive disorder (MDD) is characterized by several distinct stages:
an acute phase for 12 weeks, [...]
Continue reading " Psychotherapy and Psychopharmacology: Duloxetine Versus Placebo "
Effects of Atomoxetine generic and Methylphenidate on Sleep in Children with Attention-Deficit/ Hyperactivity Disorder
Author: R. Bart Sangal MD, Clinical Neurophysiology Services PC, Troy, Michigan
Presenter: Virginia Sutton, PhD, Lilly Research Laboratories, Indianapolis, Indiana
Attention-deficit/hyperactivity disorder (ADHD) affects approximately 3% to 7% of school-aged children. It is characterized by inattention and/or hyperactivity and impulsivity. The disorder is thought [...]
Who can forget that great Beatles’ song (”Give Peace a Chance”), now almost 30 years old? Our academic health center, faced with spiral-ing drug costs, especially in the biotechnology sector, recently empaneled a new committee, entitled PharmacoEconomics and Cost Effectiveness (PEACE). How is this committee structured, and what might we learn from the experience of [...]
The most serious and common adverse drug reactions reported with agalsidase beta are infusion-related, consisting primarily of fever and chills or rigors, as well as tachycardia, hypertension, tightness of the throat, chest pain or tightness, dyspnea, abdominal pain, pruritus, urticaria, nausea and vomiting, lip or ear edema, and rash. These reactions occurred during the infusion [...]
Continue reading " Agalsidase beta: SAFETY AND CONTRAINDICATIONS "
Eng et al.,2001
Eng et al. evaluated agalsidase beta in a phase 1/2, single-center, open-label, dose-ranging study involving 15 patients with Fabry disease. The patients received one infusion of agalsidase beta at different dosage regimens for a total of five infusions. Results demonstrated a mean decrease in the GL-3 content of the liver by 84%, of [...]
